肝细胞癌
医学
索拉非尼
多学科方法
免疫疗法
临床试验
功能(生物学)
肝癌
肿瘤科
肝功能
DNA测序
内科学
计算生物学
癌症免疫疗法
过程(计算)
全身疗法
重症监护医学
癌
连贯性(哲学赌博策略)
酪氨酸激酶抑制剂
深度测序
靶向治疗
生物信息学
临床实习
癌症
结果(博弈论)
梅德林
作者
Marta Fortuny,Landon Long Chan,Leonardo G. da Fonseca,Ghassan K. Abou‐Alfa,Stephen Lam Chan,María Reig
出处
期刊:Hepatology
[Lippincott Williams & Wilkins]
日期:2026-06-08
卷期号:84 (4): 1078-1095
被引量:1
标识
DOI:10.1097/hep.0000000000001767
摘要
Systemic therapy for advanced HCC has evolved from a linear, stepwise algorithm into a multidimensional and truly polyhedral process shaped by treatment response, liver function, and access to therapy. This review integrates evidence from phase II and III trials and real-world studies, including more than 4000 patients across different global regions, to outline how sequencing beyond first-line immunotherapy is redefining clinical practice. After immune-based combinations, tyrosine kinase inhibitors remain active and feasible options, achieving a median overall survival of ~10-11 months, while preservation of liver function consistently determines treatment eligibility and postprogression survival. Incorporation of the Barcelona Clinic Liver Cancer concept "upon response" refines classification for patients achieving major responses or conversion and aligns staging with contemporary treatment dynamics. The CUSE framework-encompassing complexity, uncertainty, subjectivity, and emotion-reframes sequencing as an adaptive, patient-centered, and multifaceted process that integrates toxicity, feasibility, and patient values alongside efficacy. By structuring diverse clinical inputs into a unified interpretive model, CUSE supports multidisciplinary reasoning and enhances conceptual coherence in treatment sequencing. Conversion therapy and "drug-off" strategies following complete or major responses represent emerging frontiers, emphasizing that sequencing in HCC now extends beyond second-line therapy. Additionally, preserving hepatic function and applying polyhedral, data-informed decision frameworks are key to sustaining eligibility and optimizing outcomes across the continuum of care.
科研通智能强力驱动
Strongly Powered by AbleSci AI